Tebapivat
- Generic Name
- Tebapivat
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Phase 2
Not yet recruiting
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: Tebapivat Matched Placebo
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06924970
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: [13C2,15N3]-tebapivat
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06745271
- Locations
- 🇺🇸
Taha El-Shahat, Madison, Wisconsin, United States
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05490446
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇪🇸C.H. Regional Reina Sofia - PPDS, Cordoba, Spain
🇪🇸Hospital Universitario La Paz - PPDS, Madrid, Spain
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
Phase 1
Completed
- Conditions
- Healthy VolunteersAnemia, Sickle Cell
- Interventions
- Drug: AG-946 Matched Placebo
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04536792
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath